JP2005520844A - Assembly unit consisting of percutaneous treatment systems that can be separated separately - Google Patents
Assembly unit consisting of percutaneous treatment systems that can be separated separately Download PDFInfo
- Publication number
- JP2005520844A JP2005520844A JP2003577795A JP2003577795A JP2005520844A JP 2005520844 A JP2005520844 A JP 2005520844A JP 2003577795 A JP2003577795 A JP 2003577795A JP 2003577795 A JP2003577795 A JP 2003577795A JP 2005520844 A JP2005520844 A JP 2005520844A
- Authority
- JP
- Japan
- Prior art keywords
- active substance
- unit
- unit according
- base film
- storage area
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
Abstract
この発明は別々に分離できる経皮治療システムからなる組立ユニットに関する。The present invention relates to an assembly unit comprising a transdermal therapeutic system that can be separated separately.
Description
この発明が別々に分離できる経皮治療システムからなる組立ユニットに関する。 The present invention relates to an assembly unit comprising a transdermal therapeutic system that can be separated separately.
有効物質の適用が経皮的に与えられる経皮治療システムが知られている。これらは、特定の期間にわたって連続的にモニターされる間に、皮膚を介して、人または動物生体に治療有効物質を与える技術的に特定された貼付剤システムである。 Transdermal therapeutic systems are known in which the application of the active substance is given transcutaneously. These are technically specified patch systems that provide therapeutically active substances to the human or animal body through the skin while being continuously monitored over a specified period of time.
前記のシステムでは、有効物質はマトリックスに分散していてもよく、有効物質貯蔵域(reservoir)に見いだされてもよい。マトリックスにおいてでも有効物質貯蔵域においてでも、有効物質は液体、半固体または固体の形態でもよく、または対応する有効物質製剤として使われてもよい。 In the system described above, the active substance may be dispersed in a matrix and may be found in an active substance reservoir. Whether in the matrix or in the active substance storage area, the active substance may be in liquid, semi-solid or solid form or used as a corresponding active substance formulation.
周知の経皮治療システムは有効物質を制御された方法で放つように特定の前もって決定された投薬量で含んでいる。患者の必要に応じて有効物質を個々別々の量投与することは、未解決の問題である。 Known transdermal therapeutic systems contain a specific predetermined dosage so as to release the active substance in a controlled manner. It is an open question to administer individual and different amounts of active substance according to the patient's needs.
従来の技術によれば、個別の投薬量は種々の方法で与えられる。 According to the prior art, individual dosages are given in various ways.
ＤＥ（ドイツ）−Ｕ−２９５１１ ８７８の教えることによれば、細片状の経皮治療システムが提案され、患者の必要量に応じて１小片を分離することができる。その分離は有効物質含有領域で起きる。有効物質の量がその結果失われる可能性があり、またごく小さな不正確な分離でも有効物質の投薬量が変化する可能性がある。そのために、正確な投薬量を与えることは不可能である。 According to the teaching of DE (Germany) -U-29511 878, a strip-like percutaneous treatment system is proposed, in which one piece can be separated according to the patient's requirements. The separation occurs in the active substance containing region. The amount of active substance can be lost as a result and the dosage of active substance can change even with very small inaccuracies. Therefore, it is impossible to give an exact dosage.
特許公報 ＤＥ（ドイツ）１９７３３９８１は経皮治療システムを開示するが、その有効物質含有領域は投薬量を減らすために部分的に覆われていてもよい。しかし、これでは有効物質の一部が使われないという結果を生む恐れがある。皮膚との有効物質含有領域の接触も損なわれる可能性がある。 The patent publication DE (Germany) 19733981 discloses a transdermal therapeutic system, but its active substance-containing area may be partially covered to reduce the dosage. However, this may have the result that some of the active substance is not used. Contact with the active substance-containing area with the skin may also be impaired.
特許公報ＤＥ（ドイツ）１９９ ００ ６４５は別々に分離できる、有効物質を含む複数のマトリックス部からなる経皮治療システムを開示するが、該マトリックス部の各々は、粘着性の細片を使って、別々にまたは複数を一度に提供することができる。しかしながら、マトリックスシステムおよび分離した粘着性の細片の使用法は複雑であって、接着物質含有マトリックス部と皮膚との最適な接触は保証されない。 The patent publication DE (Germany) 199 00 645 discloses a transdermal therapeutic system consisting of a plurality of matrix parts containing active substances, which can be separated separately, each of the matrix parts using adhesive strips, Separately or more than one can be provided at a time. However, the use of the matrix system and the separate sticky strips is complex and optimal contact between the adhesive-containing matrix part and the skin is not guaranteed.
従って、目的は、使いやすく、患者の必要に応じて有効物質を失うことなく有効物質の個別の投薬量を正確に与えることを可能にし、かつ確かな皮膚接触を保証する、経皮的に与えられる有効物質を適用するための経皮治療システムを提供することと設定された。 Therefore, the aim is to provide a transcutaneous, easy to use, allowing the individual dosage of the active substance to be accurately given as needed by the patient without losing the active substance and ensuring a reliable skin contact. It was set up to provide a transdermal therapeutic system for applying the active substance.
この発明によれば、前記の目的は、別々に分離できる少なくとも２つの経皮治療システムからなる組立ユニットであって、
それぞれのシステムが、
ａ)有効物質に対して不透過性であるベースフィルム、
ｂ)少なくとも部分的に前記ベースフィルムを覆う、有効物質貯蔵域または有効物質含有マトリックスを有し、そして有効物質を含まない周縁域を有する、接着能力を有する層、
および、任意的にあってもよいものとして、
ｃ)少なくとも部分的に、前記の接着能力を有する層を覆う取り外し可能な保護膜、
を有してなり、
前記の別々に分離できる経皮治療システムが有効物質を含まないそれらに隣接した縁域に分離機構を有することを特徴とする上記ユニットを提供することによって達成される。
According to the invention, the object is an assembly unit comprising at least two transdermal therapeutic systems that can be separated separately,
Each system is
a) a base film that is impermeable to the active substance,
b) a layer having an adhesive capacity, having an active substance storage area or an active substance-containing matrix, at least partially covering the base film, and having a peripheral area free of active substance;
And optionally,
c) a removable protective film covering, at least in part, the layer having the adhesive capability;
Having
Said separately separable transdermal therapeutic system is achieved by providing said unit characterized in that it has a separation mechanism in the marginal area adjacent to them that does not contain active substance.
別々に分離できる経皮治療システムを、この発明による組立ユニットから切り離すための、線状であるミシン目があることが好ましい。 Preferably there is a perforation that is linear to separate the transdermal therapeutic system that can be separated separately from the assembly unit according to the invention.
別々に分離できるシステムをこの発明のユニットから分離する機構を示す裁断マークがベースフィルムおよび／またはカバーフィルムにあることも好ましい。分離機構は、各々の場合に、各組立経皮治療システムが本発明によるユニットから完全に分離可能なように、配置されていることが好ましい。 It is also preferred that the base film and / or the cover film have a cut mark indicating the mechanism for separating the separately separable system from the unit of the present invention. The separation mechanism is preferably arranged in each case so that each assembled percutaneous treatment system is completely separable from the unit according to the invention.
経皮的に与えることができる有効物質、例えば、コルチコステロイド(corticosteriods)、鎮痛剤、鎮静剤、鎮静剤、抗生物質、麻酔剤、抗ウイルス薬、抗菌物質、殺真菌剤、ビタミン、抗けいれん薬、性ホルモン、ニコチン、精神薬理学剤(psychopharmacological agents)、冠状血管拡張薬、抗関節炎剤(anti-arthritic agents)、抗喘息薬、抗うつ薬、糖尿病薬、抗ヒスタミン薬、抗炎症剤および／または抗片頭痛薬(antimigraine agents)、が適している。 Active substances that can be given transdermally, e.g. corticosteriods, analgesics, sedatives, sedatives, antibiotics, anesthetics, antivirals, antibacterials, fungicides, vitamins, anticonvulsants Drugs, sex hormones, nicotine, psychopharmacological agents, coronary vasodilators, anti-arthritic agents, anti-asthma drugs, antidepressants, diabetes drugs, antihistamines, anti-inflammatory drugs and // Antimigraine agents are suitable.
この発明のユニットまたは分離したシステムは、痛みと闘うことに適していることが好ましい。 The unit or separate system of the present invention is preferably suitable for combating pain.
別々に分離できる経皮システムは、ベースフィルムと、その上に設けられた、接着能力を有し、有効物質含有マトリックスまたは有効物質貯蔵域とを備え、さらに任意的であるが保護膜を備えた層とを有してなる。 A separately separable transdermal system comprises a base film and an adhesive capacity, active substance-containing matrix or active substance storage area provided thereon, and optionally, a protective film. And a layer.
接着能力を有する層は、少なくともある特定の部分において、好ましくは完全に、接着能力を有する成分、好ましくは感圧接着剤成分含有マトリックス材料からなってもよく、そして有効物質含有領域を備える。該有効物質含有領域は有効物質を含まない周縁域によって囲まれる。 The layer having adhesive capability may consist of a component having adhesive capability, preferably a pressure sensitive adhesive component-containing matrix material, at least in certain parts, and comprises an active substance-containing region. The active substance-containing region is surrounded by a peripheral area that does not contain an active substance.
有効物質に対して不透過性であるベースフィルムは、好ましくは、柔軟で伸張可能で耐久性を有し、良好な通気性を備えた材料で作られている。織物タイプの布はくが特に好ましい。ベースフィルムは着色されていてもよく、好ましくは皮膚色であってもよい。 The base film that is impermeable to the active substance is preferably made of a material that is flexible, stretchable, durable and has good breathability. Woven type fabric is particularly preferred. The base film may be colored and preferably may be a skin color.
「有効物質に対して不透過性である」との用語は、少なくとも有効物質含有マトリックスが存在する領域でベースフィルムが有効物質に対して不透過性であることを意味する。ベースフィルム自身が有効物質に対して不透過性でない場合は、有効物質に対して不透過性である障壁層がマトリックス層または有効物質貯蔵域とベースフィルムとの間に用いられる必要がある。 The term “impermeable to the active substance” means that the base film is impermeable to the active substance at least in the region where the active substance-containing matrix is present. If the base film itself is not impermeable to the active substance, a barrier layer that is impermeable to the active substance must be used between the matrix layer or active substance storage area and the base film.
前記の障壁層がフィルム形成性ポリマーを構成成分として含むことが好ましい。 The barrier layer preferably contains a film-forming polymer as a constituent component.
層ｂのマトリックス材料は、親油性ポリマー系または親水性ポリマー系のものでよい。親水性のポリマーマトリックスは水を含んでもよくて、好ましくはゲルである。マトリックス材料は架橋性のポリマー、好ましくは合成樹脂、シリコーンゴム、またはゴムでもよく、例えばスチレン−イソプレン−スチレンブロック共重合体、シリコーン、ポリアクリレート、ポリウレタン、ポリビニルエチルエーテル、ポリ塩化ビニール、ポリビニルアルコール、ポリビニルピロリドンポリエステル、ポリプロピレンおよび／または多糖類が挙げられる。ポリアクリレートが特に好ましい。 The matrix material of layer b may be of lipophilic polymer type or hydrophilic polymer type. The hydrophilic polymer matrix may contain water and is preferably a gel. The matrix material may be a crosslinkable polymer, preferably a synthetic resin, silicone rubber, or rubber, such as styrene-isoprene-styrene block copolymer, silicone, polyacrylate, polyurethane, polyvinyl ethyl ether, polyvinyl chloride, polyvinyl alcohol, Mention may be made of polyvinylpyrrolidone polyester, polypropylene and / or polysaccharides. Polyacrylate is particularly preferred.
接着能力を有する層を作り出すために使われる接着能力を有する成分は好ましくは皮膚適合型のポリマー接着剤、特に好ましくはホットメルトのような感圧接着剤である。 The adhesive capable component used to create the adhesive capable layer is preferably a skin compatible polymer adhesive, particularly preferably a pressure sensitive adhesive such as hot melt.
接着能力を有する層を作り出すために、接着能力を有する成分を既知量で前述のマトリックス材料と混ぜてもよく、そして有効物質含有マトリックス領域を作り出すために有効物質を加えてもよい。有効物質を含まない周縁域が存在するように、有効物質含有マトリックス領域がベースフィルムに当てられる。このように当てた後に、マトリックス材料を、必要なら架橋してもよい。有効物質またはマトリックス中に見出される物質は、液体、半固体または固体の状態、分散状態であってもよいし、あるいは、通常の補助剤物質を有効物質製剤として加えることによって、対応する製剤として包含させてもよい。 In order to create a layer with adhesive ability, the ingredients with adhesive ability may be mixed with the aforementioned matrix material in known amounts, and active substances may be added to create an active substance-containing matrix region. The active substance-containing matrix region is applied to the base film so that there is a peripheral area that does not contain the active substance. After such application, the matrix material may be cross-linked if necessary. The active substance or substance found in the matrix may be in the liquid, semi-solid or solid state, dispersed state, or included as a corresponding formulation by adding the usual auxiliary substances as the active substance formulation You may let them.
有効物質の経皮輸送を強化または容易にする化合物を通常の補助剤物質として使用してもよい。前記の補助剤物質を有効物質と混ぜるか、または有効物質含有マトリックス層から独立している層に見いだされるようにしてもよい。 Compounds that enhance or facilitate transdermal delivery of the active substance may be used as conventional adjunct substances. Said adjuvant material may be mixed with the active substance or may be found in a layer independent of the active substance-containing matrix layer.
経皮的に適用される有効物質が接着能力を有する層中の有効物質貯蔵域に位置している限りにおいて、前記の貯蔵域は接着能力を有する層に埋め込まれるのが好ましい。 接着能力を有する成分とリストした前述のポリマー接着剤は前記の層に対して適切な接着剤である。 As long as the active substance applied percutaneously is located in the active substance storage area in the layer having adhesive ability, the storage area is preferably embedded in the layer having adhesive ability. The aforementioned polymer adhesives listed as components having adhesive ability are suitable adhesives for the aforementioned layers.
有効物質貯蔵域は、有効物質貯蔵域の膜を通して拡散することができ、妨げられない溶液として有効物質または対応する有効物質製剤を含むことが好ましい。マトリックス材料として使うことができる前述のポリマーは適当な膜材料である。 The active substance storage area preferably diffuses through the membrane of the active substance storage area and preferably comprises the active substance or the corresponding active substance formulation as an unhindered solution. The aforementioned polymers that can be used as matrix material are suitable membrane materials.
層ｂ)の有効物質含有マトリックス領域が接着能力を有する成分を含有しない場合には、例外的に、該経皮システムを、接着能力を有する成分がマトリックス成分として縁部の領域―有効物質を含まない―にだけ見いだされるように構成されてもよい。 In the case where the active substance-containing matrix region of layer b) does not contain any component with adhesive ability, the transdermal system is exceptionally excluded if the component with adhesive ability contains the marginal region-active substance as a matrix component. It may be configured to be found only in the absence.
経皮のシステムを組み立てるために使われるすべての材料、しかし特に皮膚と接触する材料は皮膚適合型で生理的に安全である必要がある。 All materials used to assemble transdermal systems, but especially those that come into contact with the skin, must be skin compatible and physiologically safe.
この発明よる経皮治療システムは通常少なくとも有効物質を与える領域に、そして好ましくは接着能力を有する層全体に渡って、適用の前に容易に取り除くことができる保護フィルムを有する。前記の保護膜は好ましくは紙でできているか、または容易に付着する生理的に安全なプラスチック材料のフィルムである。 The transdermal therapeutic system according to the invention usually has a protective film that can be easily removed prior to application, at least in the area providing the active substance, and preferably over the entire layer having adhesive ability. Said protective film is preferably made of paper or a film of a physiologically safe plastic material which is easily attached.
別々に分離できる経皮治療システムからなるこの発明の組立ユニットは、それぞれのシステムに有効物質を等量含んでいることが好ましく、その結果、患者またはユーザーのために個別の要求に応じた適用がかなり容易になる。このことは、有効物質への要求が、例えば反復する疼痛の発作の場合のように変化する場合、または投薬量を減らしながら治療を縮小させる必要がある場合に、特に当てはまる。 The assembly unit of the present invention consisting of transdermal therapeutic systems that can be separated separately preferably contains equal amounts of active substance in each system, so that it can be adapted to individual requirements for patients or users. It becomes quite easy. This is especially true when the demand for active substances changes, such as in the case of repeated pain attacks, or when treatment needs to be reduced while reducing dosage.
この目的で、この発明による複数の経皮治療システムの適用は適切な初期治療を可能にし、そして、次の過程ではシステムの数を減らすことによって有効物質量を治療患者自身が容易に適切に減少することができる。 For this purpose, the application of multiple transcutaneous treatment systems according to the present invention allows an appropriate initial treatment, and in the next step, the treatment patient himself can easily and appropriately reduce the amount of active substance by reducing the number of systems. can do.
別々に分離できる経皮の、治療システムからなるこの発明による組立ユニットは好ましくは包装されるが、必要な場合には滅菌包装も可能である。 The assembly unit according to the invention consisting of a percutaneous, therapeutic system that can be separated separately is preferably packaged, although sterilized packaging is possible if required.
図１は、４つの別々に分離できる経皮治療システムからなる、この発明によるユニット（１）の平面図を示す。 FIG. 1 shows a plan view of a unit (1) according to the invention consisting of four separately separable transdermal therapeutic systems.
図２は、２つの別々に分離できる経皮治療システムからなる、この発明によるユニット（１）の平面図を示す。 FIG. 2 shows a plan view of a unit (1) according to the invention consisting of two separately separable transdermal therapeutic systems.
図１および図２の両方において、矢印は残っているユニット（１）それぞれの別々に分離できる経皮システムの分離ライン（４）、この場合ミシン目、の方向を指している。別々に分離できるシステムの各々が有効物質含有マトリックス領域（３）または有効物質含有貯蔵域を備えていて、これは接着能力を有し有効物質を含まない周縁域（２）によって囲まれている。ベースフィルムおよび任意的にあってもよい保護フィルムは図１および２に別々には示されていない。 In both FIGS. 1 and 2, the arrows point in the direction of the separation line (4) of the percutaneous system, which in this case is perforated, of each remaining unit (1). Each separately separable system comprises an active substance-containing matrix area (3) or an active substance-containing storage area, which is surrounded by a peripheral area (2) that has adhesive capacity and does not contain an active substance. The base film and the optional protective film are not shown separately in FIGS.
Claims (8)
ａ)有効物質に対して不透過性であるベースフィルム、
ｂ)少なくとも部分的に前記ベースフィルムを覆う、有効物質貯蔵域または有効物質含有マトリックスを有し、そして有効物質を含まない周縁域を有する、接着能力を有する層、
および、任意的にあってもよいものとして、
ｃ)少なくとも部分的に、前記の接着能力を有する層を覆う取り外し可能な保護膜、
を有してなり、
前記の別々に分離できる経皮治療システムが有効物質を含まないそれらに隣接した縁域に分離機構を有することを特徴とする上記ユニット。 An assembly unit comprising at least two transdermal therapeutic systems that can be separated separately, each system comprising:
a) a base film that is impermeable to the active substance,
b) a layer having an adhesive capacity, having an active substance storage area or an active substance-containing matrix, at least partially covering the base film, and having a peripheral area free of active substance;
And optionally,
c) a removable protective film covering, at least in part, the layer having the adhesive capability;
Having
Said unit characterized in that said separately separable transdermal therapeutic system has a separating mechanism in the marginal area adjacent to them which does not contain active substance.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10213772A DE10213772A1 (en) | 2002-03-27 | 2002-03-27 | Cohesive unit of singular transdermal therapeutic systems |
| PCT/EP2003/003004 WO2003079962A2 (en) | 2002-03-27 | 2003-03-22 | Assembled unit consisting of individually separable transdermal therapeutic systems |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2005520844A true JP2005520844A (en) | 2005-07-14 |
Family
ID=27816006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003577795A Pending JP2005520844A (en) | 2002-03-27 | 2003-03-22 | Assembly unit consisting of percutaneous treatment systems that can be separated separately |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1490039A2 (en) |
| JP (1) | JP2005520844A (en) |
| AR (1) | AR039137A1 (en) |
| AU (1) | AU2003226695B2 (en) |
| CA (1) | CA2480683A1 (en) |
| DE (1) | DE10213772A1 (en) |
| PE (1) | PE20031015A1 (en) |
| PL (1) | PL370886A1 (en) |
| WO (1) | WO2003079962A2 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006225319A (en) * | 2005-02-17 | 2006-08-31 | Nitto Denko Corp | Patch preparation |
| KR20110135354A (en) * | 2010-06-10 | 2011-12-16 | 닥터. 수버랙 스킨＆ 헬쓰 케어 아게 | Stratiform perforated biomatrices |
| KR101802553B1 (en) | 2010-09-23 | 2017-11-28 | 모노졸 알엑스, 엘엘씨 | Method and system for forming a pharmaceutical product directly onto a packaging surface |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0400685D0 (en) * | 2004-03-19 | 2004-03-19 | Pfizer Health Ab | Means for transdermal administration of nicotine |
| DE102004045599A1 (en) * | 2004-09-17 | 2006-03-23 | Grünenthal GmbH | System for the sequential, transdermal administration of systemically active substances |
| DE202005014347U1 (en) | 2005-09-09 | 2007-01-18 | Grünenthal GmbH | Application system for an active-ingredient release system, comprises a film-forming transparent plastic foil strip detachably connected to plaster containing an active ingredient and to controlled-release agent for the active ingredient |
| DE102006011340A1 (en) * | 2006-03-09 | 2007-09-20 | Grünenthal GmbH | Active substance-containing patches with improved handling |
| DE102006054731B4 (en) | 2006-11-21 | 2013-02-28 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system for administration of the active ingredient buprenorphine and use thereof in pain therapy |
| SG10201604754VA (en) | 2011-12-12 | 2016-08-30 | Lohmann Therapie Syst Lts | Transdermal delivery system comprising buprenorphine |
| ES2599802T3 (en) | 2013-06-04 | 2017-02-03 | Lts Lohmann Therapie-Systeme Ag | Transdermal Administration System |
| WO2017201190A1 (en) | 2016-05-18 | 2017-11-23 | Shanghai Yanfeng Jinqiao Automotive Trim Systems Co. Ltd | Console assembly for vehicle interior |
| US11572723B2 (en) | 2019-02-27 | 2023-02-07 | Shanghai Yanfeng Jinqiao Automotive Triim Systems Co. Ltd. | Vehicle interior component |
| CN111359441B (en) * | 2020-03-25 | 2022-02-15 | 青岛科技大学 | Preparation method of chlorine-resistant reverse osmosis membrane filled with alkaline pH-responsive polymer nano container |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2449865B2 (en) * | 1974-10-17 | 1981-06-19 | Schering Ag Berlin Und Bergkamen, 1000 Berlin | Film-shaped medicinal product |
| EP0252459A1 (en) * | 1986-07-07 | 1988-01-13 | Schering Corporation | Compartmentalized transdermal delivery system |
| DE3630603A1 (en) * | 1986-09-09 | 1988-03-10 | Desitin Arzneimittel Gmbh | PHARMACEUTICAL AND DOSAGE FORM FOR MEDICINAL ACTIVE SUBSTANCES, REAGENTS OR THE LIKE, AND METHOD FOR THE PRODUCTION THEREOF |
| KR970008118B1 (en) * | 1987-07-09 | 1997-05-21 | 엘테에스 로오만 테라피-지스테메 게엠베하 운트 콤파니 카게 | Transdermal therapeutic system |
| DE3911617A1 (en) * | 1988-10-12 | 1990-04-19 | Klaus Brueckner | Application form for pharmaceuticals esp. for treating pain or wounds - comprises sealed packed carrier layer contg. pharmaceutical which is esp. ethereal oil |
| CA2090598A1 (en) * | 1992-03-04 | 1993-09-05 | Kirti Himatlal Valia | Titratable transdermal patch system and method for administration of therapeutic substances |
| DE4223004A1 (en) * | 1992-07-13 | 1994-01-20 | Liedtke Pharmed Gmbh | Single-dose semi-solid topical dosage form for transdermal therapy |
| US5242433A (en) * | 1992-12-07 | 1993-09-07 | Creative Products Resource Associates, Ltd. | Packaging system with in-tandem applicator pads for topical drug delivery |
| DE19503336C2 (en) * | 1995-02-02 | 1998-07-30 | Lohmann Therapie Syst Lts | Pharmaceutical form for delivering active substances to wounds, process for their preparation and their use |
| DE29511878U1 (en) * | 1995-07-22 | 1996-11-28 | Labtec Gmbh | Transdermal therapeutic systems |
| DE19900645C2 (en) * | 1999-01-11 | 2003-03-20 | Deotexis Inc | Transdermal therapeutic system |
| US6221384B1 (en) * | 1999-11-05 | 2001-04-24 | Anthony C. Pagedas | Segmented transdermal dosage unit |
| US6682757B1 (en) * | 2000-11-16 | 2004-01-27 | Euro-Celtique, S.A. | Titratable dosage transdermal delivery system |
-
2002
- 2002-03-27 DE DE10213772A patent/DE10213772A1/en not_active Withdrawn
-
2003
- 2003-03-22 AU AU2003226695A patent/AU2003226695B2/en not_active Ceased
- 2003-03-22 WO PCT/EP2003/003004 patent/WO2003079962A2/en active Search and Examination
- 2003-03-22 CA CA002480683A patent/CA2480683A1/en not_active Abandoned
- 2003-03-22 EP EP03744842A patent/EP1490039A2/en not_active Withdrawn
- 2003-03-22 PL PL03370886A patent/PL370886A1/en not_active Application Discontinuation
- 2003-03-22 JP JP2003577795A patent/JP2005520844A/en active Pending
- 2003-03-25 PE PE2003000296A patent/PE20031015A1/en not_active Application Discontinuation
- 2003-03-25 AR ARP030101040A patent/AR039137A1/en unknown
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006225319A (en) * | 2005-02-17 | 2006-08-31 | Nitto Denko Corp | Patch preparation |
| KR20110135354A (en) * | 2010-06-10 | 2011-12-16 | 닥터. 수버랙 스킨＆ 헬쓰 케어 아게 | Stratiform perforated biomatrices |
| KR101886820B1 (en) | 2010-06-10 | 2018-08-08 | 메드스킨 솔루션즈 닥터. 수버랙 아게 | Stratiform perforated biomatrices |
| KR101802553B1 (en) | 2010-09-23 | 2017-11-28 | 모노졸 알엑스, 엘엘씨 | Method and system for forming a pharmaceutical product directly onto a packaging surface |
Also Published As
| Publication number | Publication date |
|---|---|
| DE10213772A1 (en) | 2003-10-09 |
| WO2003079962A2 (en) | 2003-10-02 |
| AU2003226695B2 (en) | 2008-10-02 |
| PE20031015A1 (en) | 2004-01-17 |
| AU2003226695A1 (en) | 2003-10-08 |
| AR039137A1 (en) | 2005-02-09 |
| PL370886A1 (en) | 2005-05-30 |
| CA2480683A1 (en) | 2003-10-02 |
| WO2003079962A3 (en) | 2003-12-24 |
| EP1490039A2 (en) | 2004-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6676961B1 (en) | Transdermal patch assembly | |
| JP3288762B2 (en) | Skin contact device | |
| EP0117027B1 (en) | Drug delivery device | |
| US5662925A (en) | Transdermal delivery system with adhesive overlay and peel seal disc | |
| US8802136B2 (en) | Transdermal patch incorporating active agent migration barrier layer | |
| US7049479B2 (en) | Ultra thin film transdermal/dermal or transmucosal/mucosal delivery system | |
| EP1194092B1 (en) | Exothermic topical delivery device | |
| KR910002250B1 (en) | Plaster containing active ingredients for controlles administration of active ingredients to the skin | |
| BRPI0619494A2 (en) | an adhesive affixing assembly to a patient's skin or mucosa, a system for handling a plurality of adhesive coated elements and a stacked plurality of components for the manufacture of an adhesive affixation arrangement to a patient's skin or mucosa | |
| IE59729B1 (en) | Therapeutic system, process for its production and its use | |
| JP2005520844A (en) | Assembly unit consisting of percutaneous treatment systems that can be separated separately | |
| CZ284770B6 (en) | Transdermal therapeutic system and the use thereof | |
| US20050118245A1 (en) | Assembled unit consisting of individually separable, transdermal, therapeutic systems | |
| KR19980701419A (en) | (s) -3-methyl-5- (1-methyl-2-pyrrolidenyl) -isoxazole or a transdermal therapeutic system for administering one of the pharmaceutically acceptable salts thereof | |
| AU2009353789A1 (en) | Transdermal therapeutic system | |
| US20220110885A1 (en) | Transdermal therapeutics system with barrier layer | |
| MXPA97005324A (en) | Transdermal therapeutic system for the supply of (s) -3-methyl-5- (1-methyl-2-pirrolidenyl) -isoxazole or any of its salts pharmaceutically ap |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060308 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090915 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100302 |